[Lung cancer: an update in 2010].
The year 2009 has lead to new data clearly impacting therapeutic management strategies in NSCLC. Personalized medicine is becoming a reality for patients with EGFR mutation as well as for the recruitment of patients in certain clinical trials (EML4-ALK translocation, KRAS mutation...). Maintenance trials are based on questionable statistical designs but this approach may have an interest in certain subset of patients. Little improvements are being achieved in SCLC and locally advanced NSCLC.
Besse
B
B
Institut Gustave-Roussy, Département de Médecine, F-94800 Villejuif, France. benjamin.besse@igr.fr
Vignot
S
S
Soria
J-C
JC
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000556:secondary; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy / Q000379:methods; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D000069347:Erlotinib Hydrochloride; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy*; D011799:Quinazolines / Q000627:therapeutic use; D055752:Small Cell Lung Carcinoma / Q000473:pathology / Q000556:secondary / Q000628:therapy*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D011799:Quinazolines; D000068258:Bevacizumab; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors